Decipher Biosciences
Decipher Biosciences, a Veracyte subsidiary, provides tissue-based genomic classifiers for prostate and bladder cancer, serving urologists and oncologists with the only Medicare-covered gene expression test for prostate cancer treatment decisions.
- Company typePublic
- Founded2008
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Decipher Biosciences does
Decipher Biosciences is a specialty genomic diagnostics company focused on tissue-based molecular testing for urological cancers, operating as a wholly-owned subsidiary of Veracyte, Inc. (NASDAQ: VCYT) following its 2020 acquisition. Its core product, the Decipher Prostate Genomic Classifier, is the only gene expression test covered by Medicare for informing prostate cancer treatment decisions across the care continuum, with a clinical evidence base spanning >300,000 patients tested, >115 peer-reviewed publications, and >25 ongoing prospective randomized clinical trials. The Decipher Bladder Genomic Classifier extends the franchise into bladder cancer diagnostics, and the 2026 launches of TrueMRD (muscle invasive bladder cancer recurrence monitoring) and Prosigna (breast cancer risk of recurrence) signal continued product surface expansion under the Veracyte distribution umbrella.
Decipher Biosciences firmographics
Firmographics- Name
- Decipher Biosciences
- Legal name
- Veracyte, Inc.
- Website
- https://decipherbio.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Decipher Biosciences, a Veracyte subsidiary, provides tissue-based genomic classifiers for prostate and bladder cancer, serving urologists and oncologists with the only Medicare-covered gene expression test for prostate cancer treatment decisions.
- Ownership category
- akta.pro rank
Decipher Biosciences industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Decipher Biosciences is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Decipher Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Genomic Diagnostic Testing: Revenue generated from clinical laboratory testing services including the Decipher Prostate test, Decipher Bladder test, Afirma thyroid test, and Prosigna breast cancer test. Testing revenue of $135.8M in Q4 2025 driven by growth in Decipher Prostate and Afirma diagnostic tests. Full-year 2025 revenue of $517.1M, up 16% year-over-year.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Laboratory-developed test service pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Decipher Biosciences product offering
Product offeringCore offering
Decipher Biosciences offers tissue-based molecular genomic tests that analyze gene expression patterns in tumor samples to assess cancer risk and inform treatment decisions. Its flagship Decipher Prostate Genomic Classifier evaluates risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer, and it is the only gene expression test for prostate cancer covered by Medicare. The portfolio also includes the Decipher Bladder Genomic Classifier, Afirma Genomic Sequencing Classifier for thyroid nodules, Prosigna Breast Risk of Recurrence Test, and TrueMRD for muscle invasive bladder cancer monitoring.
Product overview
Decipher Biosciences, now part of Veracyte, offers a portfolio of genomic classifier tests for cancer diagnostics. The product line includes Decipher Prostate Genomic Classifier (tissue-based molecular test for prostate cancer metastasis risk), Decipher Bladder Genomic Classifier (bladder cancer), Afirma Genomic Sequencing Classifier (thyroid nodules), Prosigna Breast Risk of Recurrence Test (breast cancer), and TrueMRD (monitoring test for muscle invasive bladder cancer). These tests use gene expression analysis to provide clinicians with actionable biological insights across the cancer care continuum including screening, diagnosis, prognosis, treatment guidance, and recurrence monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- Decipher Prostate Genomic Classifier: Tissue-based molecular test used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer. The only gene expression test covered by Medicare for prostate cancer treatment decisions across the continuum of care.
- Decipher Bladder Genomic Classifier
Products and services
- Decipher Prostate Genomic Classifier
Quantifiable outcome
- 705% improvement in Q4 net income year-over-year
- +3 more outcomes
Companies that use Decipher Biosciences
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Decipher Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Decipher Biosciences partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights4 records
Decipher Biosciences competitors and assessment
Company assessmentDirect peers
- Myriad Genetics: Oncology molecular diagnostics company offering germline and tumor profiling tests (e.g., Prolaris for prostate cancer risk). Directly comparable to Decipher as a gene-expression/prognostic testing service sold to urologists and oncologists.
- Exact Sciences: Public diagnostics company with Oncotype DX and Cologuard franchises. Comparable as a clinically validated, guideline-embedded cancer diagnostics business with Medicare-covered tests sold through a direct provider sales force.
- NeoGenomics: Specialty oncology reference laboratory offering molecular and FISH-based profiling. Comparable to Decipher as a urology/oncology-focused clinical genomic testing services provider with broad hospital and community oncology reach.
- Guardant Health: Liquid biopsy and oncology genomics company with Guardant360 and Reveal MRD products. Comparable as a next-generation oncology diagnostic, particularly relevant as a competitive substitute for tissue-based classifiers like Decipher Prostate.
- Natera: Molecular diagnostics company offering Signatera (tumor-informed MRD) and oncology tests. Comparable to Decipher in business model (Medicare-covered molecular oncology tests sold via direct sales to providers) and adjacent in MRD where Decipher is launching TrueMRD.
- Caris Life Sciences: Private molecular profiling company offering MI Profile and Caris Assure for oncology. Comparable to Decipher as a tumor profiling service competing for the same urology and oncology ordering physicians.
- MDxHealth: Specialized urology diagnostics company offering SelectMDx, ConfirmMDx, and GPS (Genomic Prostate Score). Closest direct peer to Decipher with overlapping prostate cancer risk stratification tests sold to the same urologist channel.
Broad incumbents
- Foundation Medicine (Roche): Subsidiary of Roche offering FoundationOne CDx and Liquid CDx comprehensive genomic profiling. Comparable as a broad-incumbent in tumor profiling/molecular diagnostics, addressing the same oncologist customers with overlapping indications.
- Genomic Health (now Exact Sciences): Oncotype DX developer, now part of Exact Sciences. Comparable as the established precedent for Medicare-covered gene expression oncology tests embedded in clinical guidelines, sharing Decipher's go-to-market archetype.
Others
- Bio-Techne: Life sciences tools and diagnostics company with reagents, ELISA kits, and ExoDx prostate test. Comparable as an enabling diagnostic supplier in prostate cancer risk assessment, partially overlapping Decipher's urology focus.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Decipher Biosciences social profiles
Digital presenceDecipher Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Decipher Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
Decipher Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Decipher Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Decipher Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Decipher Biosciences
What does Decipher Biosciences do?
Decipher Biosciences offers tissue-based molecular genomic tests that analyze gene expression patterns in tumor samples to assess cancer risk and inform treatment decisions. Its flagship Decipher Prostate Genomic Classifier evaluates risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer, and it is the only gene expression test for prostate cancer covered by Medicare. The portfolio also includes the Decipher Bladder Genomic Classifier, Afirma Genomic Sequencing Classifier for thyroid nodules, Prosigna Breast Risk of Recurrence Test, and TrueMRD for muscle invasive bladder cancer monitoring.
Is Decipher Biosciences a public or private company?
Decipher Biosciences is a public company. It is classified as corporate owned and is currently operating.
When was Decipher Biosciences founded?
Decipher Biosciences was founded in 2008. It employs 51 to 100 people.
Where is Decipher Biosciences based?
Decipher Biosciences is headquartered in San Diego, United States, in the North America region.
How does Decipher Biosciences make money?
One revenue line is on record: genomic Diagnostic Testing.
Who are Decipher Biosciences's main competitors?
Direct peers on record are Myriad Genetics, Exact Sciences, NeoGenomics, Guardant Health, Natera, Caris Life Sciences and MDxHealth. Broad incumbents are Foundation Medicine (Roche) and Genomic Health (now Exact Sciences). Bio-Techne is listed as an others.
Does Decipher Biosciences have an API?
No public API is recorded for Decipher Biosciences.
What industry is Decipher Biosciences in?
Decipher Biosciences's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk). Its NAICS code is 621511 and its SIC code is 2835.